论文部分内容阅读
目的探讨慢性乙型肝炎(HBV)重叠戊型肝炎(HEV)采取牛磺酸熊去氧胆酸治疗的疗效。方法选取62例2010年3月—2015年3月来河南省平煤神马医疗集团总医院的HBV重叠HEV感染患者,根据治疗方式不同分为对照组与试验组,两组均给予常规治疗,对照组加用恩替卡韦片治疗,试验组给予牛磺酸熊去氧胆酸胶囊治疗,观察两组临床疗效。采用SPSS 19.0软件分析及处理数据,计量资料用均数±标准差(±s)表示,组间比较采用t检验,计数资料采用率表示,组间比较以χ~2检验,P<0.05为差异有统计学意义。结果试验组较对照组临床疗效显著(P<0.05),分别为93.5%和80.6%;治疗6个月时,试验组天冬氨酸转氨酶(AST)、丙氨酸氨基转移酶(ALT)、血清胆红素(TBi L)、碱性磷酸酶(ALP)均显著低于对照组(P<0.05);同时,试验组较对照组住院时间明显缩短(P<0.05),分别为(33.36±6.92)d和(24.22±6.83)d;试验组并发症发生率、重症肝炎发生率、病死率、不良反应发生率分别为6.5%、3.2%、12.9%、6.5%,明显低于对照组19.4%、16.1%、45.2%、22.6%,差异有统计学意义(P均<0.05)。结论慢性乙型肝重叠戊型肝炎感染患者采取牛磺酸熊去氧胆酸治疗,疗效较为显著,可有效改善患者肝功能,缩短住院时间,改善疾病预后,同时不良反应少,具有推广价值。
Objective To investigate the therapeutic effect of ursodeoxycholic acid on chronic hepatitis B (HBV) overlapping hepatitis E (HEV). Methods Sixty-two patients with HBV overlap HEV infection from PingMao Shenma Medical Group General Hospital of Henan Province from March 2010 to March 2015 were divided into control group and experimental group according to different treatment methods. Both groups were given routine treatment, The control group plus entecavir tablets, the experimental group was given taurodeoxycholic acid capsules treatment, the two groups were observed clinical curative effect. SPSS 19.0 software was used to analyze and process the data. The measurement data were expressed as mean ± standard deviation (± s). The t test was used to compare the data between groups. The difference was statistically significant. Results The clinical efficacy of the experimental group was significantly higher than that of the control group (93.5% and 80.6%, respectively). At 6 months, the AST, ALT, Serum bilirubin (TBiL) and alkaline phosphatase (ALP) were significantly lower than those of the control group (P <0.05). Meanwhile, the hospitalization time of the experimental group was significantly shorter than that of the control group (P <0.05) 6.92) d and (24.22 ± 6.83) d, respectively. The incidence of complication, the incidence of severe hepatitis, case fatality and adverse reactions in the experimental group were 6.5%, 3.2%, 12.9% and 6.5% %, 16.1%, 45.2% and 22.6%, respectively. The difference was statistically significant (all P <0.05). Conclusion The treatment of patients with chronic hepatitis B overlap hepatitis E infection with ursodeoxycholic acid taurine significantly more effective in improving liver function, shortening the hospital stay, improving the prognosis of the disease, with fewer adverse reactions, and has the promotion value.